Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Summary

The main purpose of this study was to evaluate the efficacy and safety of treatment with famitinib plus SHR6390 and endocrine therapy for hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor (HER) 2 - negative advanced breast cancer.

Timeline

Start

2021-12-08

Primary completion

2024-07-03

Completion

2024-07-03

Publications

• Zhang M, Niu L, Lyu H, Liu Z, Zeng H, Lu Z, Chen X, Qiao J, Yuan P, Zhao S, Sun H, Wang J, Feng Y, Yan M. Addition of angiogenesis inhibitors to CDK4/6 inhibitors and fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer. Chin Med J (Engl). 2026 Jul 7. doi: 10.1097/CM9.0000000000004191. Online ahead of print.

Drugs

Indications